WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the int ... Show More
Sep 28
Sir Michael Moritz on ‘Auslander,’ Identity and Life as an Outsider
As a longtime partner and former chairman of the legendary Silicon Valley venture capital firm Sequoia, Sir Michael Moritz had a direct hand in building the modern internet. His early investments in companies like PayPal, Google, and YouTube earned him a reputation as a kingmaker ... Show More
1h 3m
Sep 21
AI Agents Went Rogue. Should We Hit the Panic Button?
Are the people building AI going to kill us all? That's the question sparking debate across the country right now. While fears of an AI doomsday aren’t new, they broke into the mainstream this month after Jacob Coxon, a 27-year-old British researcher, publicly quit his job at Ant ... Show More
1h 1m
Apr 2024
Can WeightWatchers survive the Wegovy era?
<p>WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the ... Show More
17m 23s
Feb 2024
The Big Business Behind Weight Loss Drugs
It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show More
33m 54s
Oct 2023
Semaglutide: Decoding the hype around the weight loss wonder drug
<p>From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becomin ... Show More
32m 7s
Apr 2023
Encore: Diet Wars | Dieting 3.0 | 5
First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ... Show More
39m 12s
Nov 2023
33. The Ozempic Trade: "Health" and Body Image on Wall Street Feat. Lindsey Lusson
Send us Fan Mail Ozempic and similar drugs are dominating the conversation about culture, health, and financial markets right now. But what does it mean for Wall Street --- not just for investors, but also in terms of its impact on the social norms of the industry? **TRIGGER WARN ... Show More
1h 3m